Phase II Study of Paclitaxel plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma

PURPOSE: To determine the efficacy and toxicity of the protein kinase C inhibitor bryostatin-1 plus paclitaxel in patients with advanced pancreatic carcinoma. METHODS: Each treatment cycle consisted of paclitaxel 90 mg/m2 by intravenous (IV) infusion over 1 hour on days 1, 8, and 15, plus bryostatin...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lam, Anthony, Sparano, Joseph A., Vinciguerra, Vincent, Ocean, Allyson J., Christos, Paul, Hochster, Howard, Camacho, Fernando, Goel, Sanjay, Mani, Sridhar, Kaubisch, Andreas
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3555556/
https://ncbi.nlm.nih.gov/pubmed/19738452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3181a31920
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires